What people are reporting about MK-677

There is a version of this that is easy to tell. Someone finds r/peptides or r/sarmssourcetalk in their late thirties, reads through threads about growth hormone secretagogues, and arrives at MK-677 because it is the only one that doesn't require a syringe. They order from a research chemical supplier, start 25 mg before bed, and wake up the next week reporting vivid dreams and a sense of sleep depth they haven't experienced since their twenties. The scale is up three pounds by day ten. Their face is puffier in the morning. They're hungrier than usual. They're also, they report, sleeping better than they have in years.

This is a real pattern in the community. It's one of the most consistent narrative arcs in MK-677 discussion, and it appears across platforms — Reddit threads, Longecity forums, bodybuilding discussion boards, longevity communities — often enough that it can't be dismissed as coincidence. It's also not the whole picture. The community conversation around MK-677 is more complicated than the first-week enthusiast report, and the complications are important.

The sleep effect is where almost everyone starts. Reports of vivid, intense dreams and deeper subjective sleep quality in the first two to four weeks of MK-677 use are among the highest-volume early observations in community discussion. People describe a qualitative shift — falling into sleep more completely, waking less, experiencing more memorable and narrative-rich dreaming that they interpret as deeper REM, and feeling more genuinely restored on waking. This is consistent with what the clinical literature on MK-677 and slow-wave sleep showed in the Copinschi trials. The community is not wrong to be noticing something. The clinical mechanism — GHS-R1a activation amplifying the GH-sleep coupling — is real.

What the community is also doing is interpreting self-reported experience through confirmation bias, reporting bias, and the particular optimism that comes with having made a decision and invested money in it. The people who had a bad experience or no experience with MK-677 sleep effects are less consistently represented in forum threads than the people who had a positive one. This is not a criticism of those individuals. It is an inherent feature of community reporting that anyone reading these accounts should hold in mind. The positive reports are genuine. The population they represent is filtered.

The hunger is almost universally noted, and the community has reached a working consensus: take MK-677 in the evening, as close to sleep as manageable, to keep the appetite stimulation from disrupting daytime eating patterns. Ghrelin is the hunger hormone. MK-677 activates the ghrelin receptor. These effects are not separable. At 25 mg — the dose most commonly reported in the community, despite the clinical trials using a range from 10 to 25 mg — the appetite stimulation can be substantial, particularly in the first weeks. Many reports describe feeling genuinely hungry in ways that are difficult to manage. People who are in a fat-loss phase and have come to MK-677 for its potential body composition effects often find the appetite increase is working directly against their goal. The community response is either dose reduction or acceptance, depending on the objective.

The water retention conversation — called "MK bloat" in most forums — is the most discussed side effect and has its own body of community wisdom. Reports describe facial puffiness, particularly noticeable in morning photos, ankle swelling, and a weight gain of two to five pounds that arrives in the first two weeks and doesn't look or feel like muscle. Most people report that this moderates over weeks, though it rarely disappears entirely during active use. Lower doses — 10 mg — are commonly reported to produce significantly less retention than 25 mg, sometimes with what users describe as comparable sleep and IGF-1 effects. The community has largely converged on the view that the 25 mg dose was adopted because it appeared in clinical trials and spread through forum consensus, not because it was optimized for the side effect profile. There's a notable subset of community members who have settled at 10 mg and report fewer issues with both retention and insulin sensitivity.

The insulin sensitivity and metabolic concern is present in the community conversation, though less consistently than the sleep and retention discussions. People who test their own labs — glucose, insulin, HbA1c — report a range of outcomes. Some report no meaningful changes in fasting glucose after months of MK-677 use. Others report elevated fasting glucose that prompted them to reduce dose, cycle off, or stop entirely. A smaller subset report persistent elevation even after stopping. The community-positivity bias is particularly worth noting here: people who discontinued MK-677 due to metabolic concerns may be less likely to return to forums and report that outcome than people who are continuing and satisfied. The glucose discussion in forums likely underrepresents the negative metabolic experiences.

The IGF-1 conversation is where the most technically sophisticated community members engage. A meaningful number of MK-677 users run their own IGF-1 panels before starting and at intervals during use — a behavior that would be unremarkable in a clinical trial and is unusual enough in a consumer population to be worth noting. Reports of IGF-1 going from low-normal to mid-range or upper-normal after several weeks of MK-677 use are common and consistent with what the clinical literature would predict. Some users aim for specific IGF-1 targets — often discussed in terms of the range seen in healthy young adults — and adjust dose to hit those targets. This is a more sophisticated approach than most OTC supplement use and reflects the community's engagement with the actual pharmacology. It is still self-directed, unmonitored, and without the clinical context that would make those IGF-1 numbers meaningful for that specific individual.

The cycling versus continuous debate is active. Some community members have used MK-677 continuously for years — a pattern with essentially no long-term safety data — and report sustained benefits without apparent problem. Others cycle on a pattern of several months on, several weeks off, based on theoretical concerns about pituitary responsiveness or insulin sensitivity accumulation. Neither approach has clinical validation for this compound in this population. The community has reached no consensus on whether cycling is necessary, and the individual reports in both camps are too confounded by dose, lifestyle, and baseline health to resolve the question.

The dose discussion itself has evolved. The 25 mg dose became community standard partly because it appeared in Merck's trials and partly through forum repetition. In recent years, a significant portion of community discussion has shifted toward 10 to 12.5 mg as a starting point — lower side effects, meaningful IGF-1 response in most people, easier to sustain. The bodybuilding subsets still lean toward 25 mg or higher; the longevity-focused users have largely moved toward lower doses. Both of these are community conventions, not clinical protocols.

Evening dosing has essentially become the default recommendation in every major forum. The reasoning — align the compound's half-life with the overnight period to capture the sleep effects and reduce the daytime appetite impact — is mechanistically coherent. Whether it is optimal compared to morning dosing, split dosing, or other timing approaches is not established. The community decided on evening dosing and it spread; that doesn't mean it's wrong, but the confidence with which it's stated as fact in forums exceeds the evidence behind it.

What the community conversation about MK-677 represents, at scale, is a large, self-organized observational study without controls, without consistent dosing, without clinical endpoints, and without systematic adverse event reporting. The patterns that emerge from it are real enough to take seriously — the sleep reports, the appetite and retention effects, the IGF-1 elevation, the insulin sensitivity concerns — but they are not clinical evidence of safety or efficacy. MK-677 is not FDA-approved for any human use. The long-term safety data does not exist. The community positivity bias means the adverse experience picture is probably softer than reality. And the decisions about starting, dosing, cycling, and monitoring this compound are decisions that should involve a prescribing provider who can run baseline labs, track changes over time, and contextualize the numbers in a complete clinical picture.

The forum conversation is context. It is not guidance. The difference matters — and it matters most when the compound in question has real metabolic effects, limited long-term safety data, and no approved clinical pathway to fall back on. Community knowledge has genuine value. It surfaces patterns the clinical trials didn't look for, documents experiences at doses and demographics the research didn't cover, and in some cases identified practical approaches — lower doses, evening timing, metabolic monitoring — that are mechanistically sensible even without controlled evidence. But community knowledge is also systematically biased toward the positive, structurally silent on the adverse experiences that caused people to leave, and incapable of the controlled comparison that would tell you whether any of it is actually causal. Hold both of those things at once, and the forums become useful without becoming authoritative.